GAMMA SECRETASE MODULATORS

1 - 91 . (canceled)

92 . A compound of the formula (I):

or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:

R 1A , G 1 , G 2 , G 3 , G 4 , (B), G, R 9 , R 10 , and W are independently selected;

letters (A) and (B) in formula (I) are reference letters to identify the rings present in formula (I);

the numbers (1), (2), (3), (4), and (5) are reference numbers to identify positions of the Ring (A); G 4 is at position (1), G 3 is at position (2), G 2 is at position (3), G 1 is at position (4) and the N is at position (5);

the moiety -G-R 10 -R 9 is bound through G to G 4 or G 3 , and when G is bound to G 4 then G 4 is a —C—, and when G is bound to G 3 then G 3 is a —C—;

the dotted line between G 1 and G 2 represents an optional bond;

Ring (B) is the ring formed from the N at position (5) and G 1 , and G 1 is carbon or N, and when G 1 is N the optional bond between G 1 and G 2 is absent;

said Ring (B) is a 4 to 8 membered heterocycloalkyl, heteroaryl, or heterocycloalkenyl ring;

said heterocycloalkyl, heterocycloalkenyl, or a heteroaryl ring Ring (B), in addition to the nitrogen common to Ring (A) and Ring (B), optionally comprises, at least one other heteroatom selected from the group consisting of: —NR 2 —, —O—, —S—, —S(O)—, and —S(O) 2 —;

said Ring (B) is optionally substituted with 1 to 6 independently selected R 21 substituents;

d is 0 or 1;

m is 0 to 6;

n is 1 to 5;

p is 0 to 5;

q is 0, 1 or 2, and each q is independently selected;

r is 1 to 5;

t is 1 or 2

W is selected from the group consisting of: —C(O)—, —S(O) 2 —, —S(O)—, and —C(═NR 2 )— (and in one example W is —C(O)—);

G is selected from the group consisting of: a direct bond, —C(O)—, —(C═NR 2 )—, —(C═C(R 6 ) 2 )—, —CHR 3 — (e.g., —CHOH), C(R 4 ) 2 , —CF 2 —, —N(R 2 )—, —O—, —S—, —S(O) t , —CR 4 (OH)—, —CR 4 (OR 4 )—, —C═C—, alkynyl, —(CH 2 ) r N(R 2 )—, —(CHR 4 ) r N(R 2 )—, —(C(R 4 ) 2 ) r N(R 2 )—, —N(R 2 )(CH 2 ) r —, —N(R 2 )(CHR 4 ) r —, —N(R 2 )(C(R 4 ) 2 ) r —, —(CH 2 ) r —O—, —(CHR 4 ) r —O—, —(C(R 4 ) 2 ) r —O—, —O—(CH 2 ) r —, —O—(CHR 4 ) r —, —O—(C(R 4 ) 2 ) r —, —(CH 2 ) r —O—C(O)—, —(CHR 4 ) r —O—C(O)—, —(C((R 4 ) 2 ) r —O—C(O)—, —C(O)—O—(CH 2 ) r —, —C(O)—O—(CHR 4 ) r —, —C(O)—O—(C(R 4 ) 2 ) r —, —C(O)NR 5 —, —O—C(O)—, —C(O)—O—, —O—C(O)—NR 5 —, —NR 5 C(O)—, —(CH 2 ) r NR 5 —C(O)—, —(CHR 4 ) r NR 5 —C(O)—, —(C(R 4 ) 2 ) r NR 5 —C(O)—, —C(O)NR 5 (CH 2 ) r —, —C(O)NR 5 (CHR 4 ) r —, —C(O)NR 5 (C(R 4 ) 2 ) r —, —NR 5 S(O) t —, —(CH 2 ) r NR 5 S(O) t —, —(CHR 4 ) r NR 5 S(O) t —, —(C(R 4 ) 2 ) r NR 5 S(O) t —, —S(O) t NR 5 —, —S(O) t NR 5 (CH 2 ) r —, —S(O) t NR 5 (CHR 4 ) r —, —S(O) t NR 5 (C(R 4 ) 2 ) r —, —NR 5 —C(O)—O—, —NR 5 —C(O)—NR 5 —, —NR 5 —S(O) t —NR 5 —, —NR 5 —C(═NR 2 )—NR 5 —, —NR 5 —C(═NR 2 )—O—, —O—C(═NR 2 )—NR 5 —, —C(R 4 )═N—O—, —O—N═C(R 4 )—, —O—C(R 4 )═N—, —N═C(R 4 )—O—, —(CH 2 ) 2-3 —, —(C(R 4 ) 2 ) 2-3 —, and —(CHR 4 ) 2-3 —, cycloalkyl, heterocycloalkyl (comprising 1 to 4 heteroatoms independently selected from the group consisting of: —O—, —NR 2 —, —S—, —S(O)—, and —S(O) 2 );

G 1 is selected from the group consisting of:

(1) —C(R 21 ) q — wherein q is 0 when the optional bond is present,

(2) —C(R 21 ) q — wherein q is 1 when the optional bond is absent,

(3) —CH— when the optional bond is absent, and

(4) —N(R 2 ) d — wherein d is 0, and the optional bond is absent;

G 2 is selected from the group consisting of: a direct bond, —C(R 21 ) q , —N(R 2 ) d —, —C(O)—, S(O), S(O) 2 , —C(N(R 2 ) 2 )—, and —C(═NR 2 )—; and with the provisos that:

(1) when the optional bond between G 1 and G 2 is not present then G 2 is not —C(N(R 2 ) 2 )—, and

(2) when the optional bond between G 1 and G 2 is present, then:

(a) q for the —C(R 21 ) q group is 0 or 1 (and when q is 0 then there is a H on the carbon), and

(b) d for the —N(R 2 ) d — group is 0; and

(c) G 2 is not a direct bond, —C(O)—, —C(═NR 2 )—)-, —S(O) 2 , or S(O)—;

G 3 is selected from the group consisting of: (a) —C(R 21 ) q wherein q is 0,

(b) —CH—, (c) —C(R 21 ) q wherein q is 1, and (d) —N(R 2 ) d wherein d is 0; and with the proviso that: when moiety G is bound to G 3 , then G 3 is carbon;

G 4 is selected from the group consisting of: (a) —C(R 21 ) q wherein q is 0,

(b) —CH—, (c) —C(R 21 ) c , wherein q is 1, and (d) —N(R 2 ) d wherein d is 0; and with the proviso that: when moiety G is bound to G 4 , then G 4 is carbon; and

provided that 0 to 2 of the G 1 , G 2 , G 3 , and G 4 moieties are —N(R 2 ) d — and each R 2 is independently selected and each d is independently selected, and provided that Ring (A) does not have three consecutive ring nitrogen atoms;

R 1A is selected from the group consisting of: alkyl-, alkenyl-, alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl, cycloalkenyl, cycloalkylalkyl-, fused benzocycloalkyl-, fused benzoheterocycloalkyl-, fused heteroarylcycloalkyl-, fused heteroarylheterocycloalkyl-, fused cycloalkylaryl, fused heterocycloalkylaryl-, fused cycloalkylheteroaryl-, fused heterocycloalkylheteroaryl-, fused benzocycloalkylalkyl-, fused benzoheterocycloalkylalkyl-, fused heteroarylcycloalkylalkyl-, fused heteroarylheterocycloalkylalkyl-, fused cycloalkylarylalkyl-, fused heterocycloalkylarylalkyl-, fused cycloalkylheteroarylalkyl-, fused heterocycloalkylheteroarylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl-, heterocyclenyl-, and heterocyclyalkyl-; wherein each of said alkyl-, alkenyl-, alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl, cycloalkenyl, cycloalkylalkyl-, fused benzocycloalkyl, fused benzoheterocycloalkyl, fused heteroarylcycloalkyl, fused heteroarylheterocycloalkyl, fused cycloalkylaryl, fused heterocycloalkylaryl, fused cycloalkylheteroaryl, fused heterocycloalkylheteroaryl, fused benzocycloalkylalkyl-, fused benzoheterocycloalkylalkyl-, fused heteroarylcycloalkylalkyl-, fused heteroarylheterocycloalkylalkyl-, fused cycloalkylarylalkyl-, fused heterocycloalkylarylalkyl-, fused cycloalkylheteroarylalkyl-, fused heterocycloalkylheteroarylalkyl-, heteroaryl, heteroarylalkyl-, heterocyclyl, heterocyclenyl and heterocyclyalkyl- R 1A groups is optionally substituted with 1-5 independently selected R 21 groups;

Each R 2 is independently selected from the group consisting of: H, —OH, —O-alkyl, —O-(halo substituted alky), —NH(R 4 ), —N(R 4 ) 2 , —NH 2 , —S(O)R 4 , S(O)(OR 4 ), —S(O) 2 R 4 , —S(O) 2 (OR 4 ), —S(O)NHR 4 , —S(O)N(R 4 ) 2 , —S(O)NH 2 , —S(O) 2 NHR 4 , —S(O) 2 N(R 4 ) 2 , —S(O) 2 NH 2 , —CN, —C(O) 2 R 4 , —C(O)NHR 4 , —C(O)N(R 4 ) 2 , —C(O)NH 2 , —C(O)R 4 , unsubstituted aryl, substituted aryl, unsubstituted heteroaryl, substituted heteroaryl, unsubstituted alkyl, substituted alkyl, unsubstituted arylalkyl-, substituted arylalkyl-, unsubstituted heteroarylalkyl-, substituted heteroarylalkyl-, unsubstituted alkenyl, substituted alkenyl, unsubstituted alkynyl, substituted alkynyl, unsubstituted cycloalkyl, and substituted cycloalkyl, wherein said substituted aryl, heteroaryl, alkyl, arylalkyl-, heteroarylalkyl-, alkenyl, alkynyl and cycloalkyl groups are substituted with 1 to 5 independently selected R 21 groups;

R 3 is selected from the group consisting of: H, —OH, halo, —O-alkyl, —O-(halo substituted alky), —NH(R 4 ), —N(R 4 ) 2 , —NH 2 , —S(R 4 ), —S(O)R 4 , —S(O)(OR 4 ), —S(O) 2 R 4 , —S(O) 2 (OR 4 ), —S(O)NHR 4 , —S(O)N(R 4 ) 2 , —S(O)NH 2 , —S(O) 2 NHR 4 , —S(O) 2 N(R 4 ) 2 , —S(O) 2 NH 2 , —CN, —C(O) 2 R 4 , —C(O)NHR 4 , —C(O)N(R 4 ) 2 , —C(O)NH 2 , —C(O)R 4 , unsubstituted aryl, substituted aryl, unsubstituted heteroaryl, substituted heteroaryl, unsubstituted alkyl, substituted alkyl, unsubstituted arylalkyl-, substituted arylalkyl-, unsubstituted heteroarylalkyl-, substituted heteroarylalkyl-, unsubstituted alkenyl, substituted alkenyl, unsubstituted alkynyl, substituted alkynyl, unsubstituted cycloalkyl, and substituted cycloalkyl, wherein said substituted aryl, heteroaryl, alkyl, arylalkyl-, heteroarylalkyl-, alkenyl, alkynyl and cycloalkyl groups are substituted with 1 to 5 independently selected R 21 groups;

each R 4 is independently selected from the group consisting of: unsubstituted aryl, substituted aryl, unsubstituted heteroaryl, substituted heteroaryl, unsubstituted alkyl, substituted alkyl, unsubstituted arylalkyl-, substituted arylalkyl-, unsubstituted heteroarylalkyl-, substituted heteroarylalkyl-, unsubstituted alkenyl, substituted alkenyl, unsubstituted alkynyl, substituted alkynyl, unsubstituted cycloalkyl, and substituted cycloalkyl, wherein said substituted aryl, heteroaryl, alkyl, arylalkyl-, heteroarylalkyl-, alkenyl, alkynyl and cycloalkyl groups are substituted with 1 to 5 independently selected R 21 groups;

each R 5 is independently selected from the group consisting of: H, unsubstituted alkyl, substituted alkyl, unsubstituted alkenyl, substituted alkenyl, unsubstituted alkynyl, substituted alkynyl, unsubstituted cycloalkyl, substituted cycloalkyl, unsubstituted aryl, substituted aryl, unsubstituted heteroaryl and substituted heteroaryl; wherein said substituted groups are substituted with one or more substituents independently selected from: R 2 ;

Each R 6 is independently selected from the group consisting of: H, halo, —CF 3 , —O-alkyl, —O-(halo substituted alky), —S(O)R 4 , —S(O)(OR 4 ), —S(O)NHR 4 , —S(O)N(R 4 ) 2 (wherein each R 4 is independently selected), —S(O)NH 2 , —S(O) 2 NHR 4 , —S(O) 2 N(R 4 ) 2 (wherein each R 4 is independently selected), —S(O) 2 NH 2 , —C(═NOR 24 )R 25 , and —S(O) 2 R 24 ; —CN, —C(O) 2 R 4 , —C(O)NHR 4 , —C(O)N(R 4 ) 2 (wherein each R 4 is independently selected), —C(O)NH 2 , —C(O)R 4 , unsubstituted aryl, substituted aryl, unsubstituted heteroaryl, substituted heteroaryl, unsubstituted alkyl, substituted alkyl, unsubstituted arylalkyl-, substituted arylalkyl-, unsubstituted heteroarylalkyl-, substituted heteroarylalkyl-, unsubstituted alkenyl, substituted alkenyl, unsubstituted alkynyl, substituted alkynyl, unsubstituted cycloalkyl, and substituted cycloalkyl, wherein said substituted aryl, heteroaryl, alkyl, arylalkyl-, heteroarylalkyl-, alkenyl, alkynyl and cycloalkyl groups are substituted with 1 to 5 independently selected R 21 groups;

R 9 is selected from the group consisting of: arylalkoxy-, heteroarylalkoxy-, arylalkylamino-, heteroarylalkylamino-, aryl, arylalkyl-, heteroaryl, heteroarylalkyl-, heterocyclyl, heterocyclenyl, and heterocyclyalkyl-, wherein each of said R 9 arylalkoxy-, heteroarylalkoxy-, arylalkylamino-, heteroarylalkylamino-, aryl, arylalkyl-, heteroaryl, heteroarylalkyl-, heterocyclyl, heterocyclenyl, and heterocyclyalkyl- is optionally substituted with 1-5 independently selected R 21 groups;

R 10 is selected from the group consisting of: aryl-, heteroaryl-, cycloalkyl-, cycloalkenyl, cycloalkylalkyl-, heterocyclyl-, heterocyclenyl-, heterocyclylalkyl-, heterocyclylalkenyl-, fused benzocycloalkyl-, fused benzoheterocycloalkyl-, fused heteroarylcycloalkyl-, fused heteroarylheterocycloalkyl-, fused cycloalkylaryl, fused heterocycloalkylaryl-, fused cycloalkylheteroaryl-, fused heterocycloalkylheteroaryl-,

wherein X is selected from the group consisting of: O, —N(R 14 )— and —S—; and wherein each of said R 10 moieties is optionally substituted with 1-5 independently selected R 21 groups; or

R 9 and R 10 are linked together to form a fused tricyclic ring system wherein R 9 and R 10 are as defined above and the ring linking R 9 and R 10 is an alkyl ring, or a heteroalkyl ring, or an aryl ring, or a heteroaryl ring, or an alkenyl ring, or a heteroalkenyl ring (for example, the tricyclic ring system is formed by linking the atoms adjacent to the atoms by which R 3 and R 4 are bound together);

R 14 is selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, heterocyclylalkyl, heterocyclylalkenyl-, aryl, arylalkyl, heteroaryl, heteroarylalkyl, —CN, —C(O)R 15 , —C(O)OR 15 , —C(O)N(R 15 )(R 16 ), —S(O)N(R 15 )(R 16 ), —S(O) 2 N(R 15 )(R 16 , —C(═NOR 15 )R 16 , and —P(O)(OR 15 )(OR 16 );

R 15A , and R 16A are independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, arylcycloalkyl, arylheterocyclyl, (R 18 ) n -alkyl, (R 18 ) n -cycloalkyl, (R 18 ) n -cycloalkylalkyl, (R 18 ) n -heterocyclyl, (R 18 ) n -heterocyclylalkyl, (R 18 ) n -aryl, (R 18 ) n -arylalkyl, (R 16 ) n -heteroaryl and (R 18 ) n -heteroarylalkyl;

R 15 , R 16 and R 17 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, arylcycloalkyl, arylheterocyclyl, (R 18 ) n -alkyl, (R 18 ) n -cycloalkyl, (R 18 ) n -cycloalkylalkyl, (R 18 ) n -heterocyclyl, (R 18 ) n -heterocyclylalkyl, (R 18 ) n -aryl, (R 18 ) n -arylalkyl, (R 18 ) n -heteroaryl and (R 18 ) n -heteroarylalkyl;

each R 18 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, —NO 2 , halo, heteroaryl, HO-alkoxyalkyl, —CF 3 , —CN, alkyl-CN, —C(O)R 19 , —C(O)OH, —C(O)OR 19 , —C(O)NHR 20 , —C(O)NH 2 , —C(O)NH 2 —C(O)N(alkyl) 2 , —C(O)N(alkyl)(aryl), —C(O)N(alkyl)(heteroaryl), —SR 19 , —S(O) 2 R 20 , —S(O)NH 2 , —S(O)NH(alkyl), —S(O)N(alkyl)(alkyl), —S(O)NH(aryl), —S(O) 2 NH 2 , —S(O) 2 NHR 19 , —S(O) 2 NH(heterocyclyl), —S(O) 2 N(alkyl) 2 , —S(O) 2 N(alkyl)(aryl), —OCF 3 , —OH, —OR 20 , —O-heterocyclyl, —O-cycloalkylalkyl, —O-heterocyclylalkyl, —NH 2 , —NHR 20 , —N(alkyl) 2 , —N(arylalkyl) 2 , —N(arylalkyl)-(heteroarylalkyl), —NHC(O)R 20 , —NHC(O)NH 2 , —NHC(O)NH(alkyl), —NHC(O)N(alkyl)(alkyl), —N(alkyl)C(O)NH(alkyl), —N(alkyl)C(O)N(alkyl)(alkyl), —NHS(O) 2 R 20 , —NHS(O) 2 NH(alkyl), —NHS(O) 2 N(alkyl)(alkyl), —N(alkyl)S(O) 2 NH(alkyl) and —N(alkyl)S(O) 2 N(alkyl)(alkyl); or

two R 18 moieties on adjacent carbons can be linked together to form a

R 19 is selected from the group consisting of: alkyl, cycloalkyl, aryl, arylalkyl and heteroarylalkyl;

R 20 is selected from the group consisting of: alkyl, cycloalkyl, aryl, halo substituted aryl, arylalkyl, heteroaryl and heteroarylalkyl;

each R 21 is independently selected from the group consisting of: alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, heterocycloalkyl, ═O, ═N—R 2 , heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halo, —CN, —OR 15 , —C(O)R 15 , —C(O)OR 15 , —C(O)N(R 15 )(R 16 ), —SR 15 , —P(O)(CH 3 ) 2 , —SO(═NR 15 )R 16 —, —SF 5 , —OSF 5 , —Si(R 15A ) 3 wherein each R 15A is independently selected —S(O)N(R 15 )(R 16 ), —CH(R 15 )(R 16 ), —S(O) 2 N(R 15 )(R 16 ), —C(═NOR 15 )R 16 , —P(O)(OR 15 )(OR 16 ), —N(R 15 )(R 16 ), -alkyl-N(R 15 )(R 16 ), —N(R 15 )C(O)R 16 , —CH 2 —N(R 15 )C(O)R 16 , —CH 2 —N(R 16 )C(O)N(R 16 )(R 17 ), —CH 2 —R 15 ; —CH 2 N(R 15 )(R 16 ), —N(R 15 )S(O)R 16A , —N(R 15 )S(O) 2 R 16A , —CH 2 —N(R 15 )S(O) 2 R 16A , —N(R 15 )S(O) 2 N(R 16 )(R 17 ), —N(R 15 )S(O)N(R 16 )(R 17 ), —N(R 15 )C(O)N(R 16 )(R 17 ), —CH 2 —N(R 15 )C(O)N(R 16 )(R 17 ), —N(R 15 )C(O)OR 16 , —CH 2 —N(R 15 )C(O)OR 16 , —S(O)R 15A , ═NOR 15 , —N 3 , —NO 2 , —S(O) 2 R 15A , —O—N═C(R 4 ) 2 (wherein each R 4 is independently selected), and —O—N═C(R 4 ) 2 wherein R 4 is taken together with the carbon atom to which they are bound to form a 5 to 10 membered ring, said ring optionally containing 1 to 3 heteroatoms selected from the group consisting of —O—, —S—, —S(O)—, —S(O) 2 —, and —NR 2 —; wherein each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl R 21 groups is optionally substituted with 1 to 5 independently selected R 22 groups;

each R 22 group is independently selected from the group consisting of alkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl, heteroaryl, halo, —CF 3 , —CN, —OR 15 , —C(O)R 15 , —C(O)OR 15 , -alkyl-C(O)OR 15 , C(O)N(R 15 )(R 16 ), —SR 15 , —S(O)N(R 15 )(R 16 ), —S(O) 2 N(R 15 )(R 16 ), —C(═NOR 15 )R 16 , —P(O)(OR 15 )(OR 16 ), —N(R 15 )(R 16 ), -alkyl-N(R 15 )(R 16 ), —N(R 15 )C(O)R 16 , —CH 2 —N(R 15 )C(O)R 16 , —N(R 15 )S(O)R 16A , —N(R 15 )S(O) 2 R 16A , —CH 2 —N(R 15 )S(O) 2 R 16A , —N(R 15 )S(O) 2 N(R 16 )(R 17 ), —N(R 15 )S(O)N(R 16 )(R 17 ), —N(R 15 )C(O)N(R 16 )(R 17 ), —CH 2 —N(R 15 )C(O)N(R 16 )(R 17 ), —N(R 15 )C(O)OR 16 , —CH 2 —N(R 15 )C(O)OR 16 , —N 3 , ═NOR 15 , —NO 2 , —S(O)R 15A and —S(O) 2 R 15A ; and

provided that:

when W is —(C═O)—, and G is bound to G 4 , and when G 1 , G 2 , G 3 , and G 4 are the same or different —C(R 21 ) q — moiety, and G is —CHR 3 —, then R 3 is not H, halo, unsubstituted aryl, substituted aryl, unsubstituted heteroaryl, substituted heteroaryl, unsubstituted arylalkyl, substituted arylalkyl, unsubstituted heteroarylalkyl, substituted heteroarylalkyl, unsubstituted alkyl, substituted alkyl, or —O-alkyl; and

when R 21 is bound to a carbon that has three other filled valences then R 21 is not ═O, ═NR 2 , or ═NOR 15 ; and

when G is bound to G 4 , and G 1 is a C(R 21 ) q group, and the carbon of said G 1 group is bound to a ═N— in Ring B, and the optional bond between G 1 and G 2 is not present, and G 2 is N(R 2 ) d , and G 3 is —C(R 21 ) q —, then G is not CHR 3 ; and

when G is bound to G 4 , and G 1 is a C(R 21 ) q group, and the carbon of said G 1 group is bound to an —NR 2 — in Ring B, and the optional bond between G 1 and G 2 is present, and G 2 is N(R 2 ) d , and G 3 is —C(R 21 ) q —, then G is not CHR 3 ; and

when G is bound to G 4 , and G 1 is a C(R 21 ) q group, and the carbon of said G 1 group is bound to a ═N— in Ring B, and G 2 is a direct bond, and G 3 is N, then G is not CHR 3 .

93 . The compound of claim 92 , wherein R 9 is selected from the group consisting of: 1gg to 13gg.

94 . The compound of claim 92 , wherein the R 9 -R 10 - moiety is selected from the group consisting of: 1bb to 40bb.

95 . The compound of claim 92 , wherein R 1A is selected from the group consisting of:

96 . The compound of claim 92 , wherein the R 9 -R 10 - moiety is:

97 . The compound of claim 92 , wherein said R 10 is selected from the group consisting of aryl and aryl substituted with one or more R 21 groups, and said R 9 group is selected from the group consisting of heteroaryl and heteroaryl substituted with one or more R 21 groups, wherein each R 21 is independently selected.

98 . The compound of claim 92 , wherein said R 10 is phenyl substituted with one R 21 group, and said R 9 is imidazolyl substituted with one R 21 group, wherein each R 21 is independently selected.

99 . The compound of claim 92 , wherein:

(a) the R 9 -R 10 - moiety is:

(b) the R 9 -R 10 - moiety is:

(c) the R 9 -R 10 - moiety is:

(d) the R 9 -R 10 - moiety is:

(e) the R 9 -R 10 - moiety is:

(f) the R 9 -R 10 - moiety is:

100 . The compound of claim 92 , wherein

R 1A is an unsubstituted aryl or an aryl substituted with one or more independently selected R 21 groups; or

R 1A is phenyl, or

R 1A is phenyl, and said phenyl is substituted with 1 to 3 independently selected R 21 groups, or

R 1A is phenyl, and said phenyl is substituted with 1 to 3 R 21 groups, and each R 21 group is the same or different halo, or

R 1A is phenyl, and said phenyl is substituted with three R 21 halo groups, and each R 21 group is the same or different halo, or

R 1A is phenyl, and said phenyl is substituted with two R 21 halo groups, and each R 21 group is the same or different halo, or

R 1A is phenyl, and said phenyl is substituted with one R 21 halo group,

R 1A is phenyl, and said phenyl is substituted with one F, or

R 1A is phenyl, and said phenyl is substituted with two F atoms, or

R 1A is phenyl, and said phenyl is substituted with three F atoms.

101 . The compound of claim 92 , wherein said R 1A is selected from the group consisting of:

102 . The compound of claim 92 , wherein said R 10 is selected from the group consisting of heteroaryl and heteroaryl substituted with one or more R 21 groups, and said R 9 group is selected from the group consisting of heteroaryl and heteroaryl substituted with one or more R 21 groups, and wherein each R 21 is independently selected.

103 . The compound of claim 92 , wherein:

(1) (a) R 1A is an aryl group, or R 1A is an aryl group substituted with 1 to 3 independently selected R 21 groups, and (b) R 10 is selected from the group consisting of aryl and aryl substituted with one or more independently selected R 21 groups, and (c) R 9 is selected from the group consisting of heteroaryl and heteroaryl substituted with one or more independently selected R 21 groups, or

(2) (a) R 1A is phenyl, or R 1A is phenyl substituted with 1 to 3 independently selected R 21 groups, and (b) R 10 is selected from the group consisting of aryl and aryl substituted with one or more independently selected R 21 groups, and (c) R 9 is selected from the group consisting of heteroaryl and heteroaryl substituted with one or more independently selected R 21 groups, or

(3) (a) R 1A is phenyl, or R 1A is phenyl substituted with 1 to 3 independently selected R 21 groups, and (b) R 10 is selected from the group consisting of phenyl and phenyl substituted with one or more independently selected R 21 groups, and (c) R 9 is selected from the group consisting of imidazolyl and imidazolyl substituted with one or more independently selected R 21 groups, or

(4) (a) R 1A is phenyl, or R 1A is phenyl substituted with 1 to 3 independently selected R 21 halo groups, and (b) R 10 is selected from the group consisting of phenyl and phenyl substituted with one or more independently selected —OR 15 groups, and (c) R 9 is selected from the group consisting of imidazolyl and imidazolyl substituted with one or more independently selected alkyl groups groups, or

(5) (a) R 1A is phenyl, or R 1A is phenyl substituted with 1 to 2 independently selected R 21 halo groups, and (b) R 10 is selected from the group consisting of phenyl and phenyl substituted with one or two independently selected —OR 15 groups, wherein R 15 is alkyl, and (c) R 9 is selected from the group consisting of imidazolyl and imidazolyl substituted with one or two independently selected alkyl groups groups, or

(6) (a) R 1A is phenyl, or R 1A is phenyl substituted with 1 R 21 halo group, and (b) R 10 is selected from the group consisting of phenyl and phenyl substituted with one or two independently selected —OR 15 groups, wherein R 15 is alkyl, and (c) R 9 is selected from the group consisting of imidazolyl and imidazolyl substituted with one or two independently selected alkyl groups groups, or

(7) (a) R 1A is phenyl, or R 1A is phenyl, substituted with 1 to 3 F, and (b) R 10 is selected from the group consisting of phenyl and phenyl substituted with one or two independently selected —OR 15 groups, wherein R 15 is methyl, and (c) R 9 is selected from the group consisting of imidazolyl and imidazolyl substituted with one or two independently selected methyl groups groups, or

(8) (a) R 1A is phenyl, or R 1A is phenyl, substituted with 1 to 2 F, and (b) R 10 is selected from the group consisting of phenyl and phenyl substituted with one or two independently selected —OR 15 groups, wherein R 15 is methyl, and (c) R 9 is selected from the group consisting of imidazolyl and imidazolyl substituted with one or two independently selected methyl groups groups.

(9) (a) R 1A is phenyl, or R 1A is phenyl, substituted with 1 F, and (b) R 10 is selected from the group consisting of phenyl and phenyl substituted with one or two independently selected —OR 15 groups, wherein R 15 is methyl, and (c) R 9 is selected from the group consisting of imidazolyl and imidazolyl substituted with one or two independently selected methyl groups groups, or

(10) R 1A is selected from the group consisting of:

wherein the R 9 -R 10 - moiety is:

(11) R 1A is selected from the group consisting of:

wherein the R 9 -R 10 - moiety is:

(12) R 1A is selected from the group consisting of:

wherein the R 9 -R 10 - moiety is:

(13) R 1A is selected from the group consisting of:

wherein the R 9 -R 10 - moiety is:

(14) R 1A is selected from the group consisting of:

wherein the R 9 -R 10 - moiety is:

104 . The compound of claim 92 , wherein:

the R 9 -R 10 - moiety is:

G is selected from the group consisting of: —C(O)—, —CH 2 —, —C(CH 3 )—, —(CHOH)—, —C(OCH 3 )—, —C(═NOCH 3 )—, —(C═NR 2 )—, —(C═C(R 6 ) 2 )—, —CHR 3 —, —NH—, —O—, —S—, —S(O)—, —S(O) 2 — and a direct bond, and W is —C(O)—.

105 . The compound of claim 92 selected from the group consisting of compounds of the formula: (IA) wherein the optional bond between G 1 and G 2 is absent, (IA) wherein the optional bond between G 1 and G 2 is present, (IB) wherein the optional bond between G 1 and G 2 is absent, (IB) wherein the optional bond between G 1 and G 2 is present, IC to IH, 2 to 9, 12 to 18, 20, 21, 40 to 43, 55, 2A to 9A, 12A to 18A, 20A, 21A, 40A to 43A, 55A, 2B to 9B, 12B to 18B, 20B, 21B, 40B to 43B, 55B, 2C to 9C, 12C to 18C, 20C, 21C, 40C to 43C, 55C, 6.2, 9.1, 10.1, 10.2, 10.3, 14.1, 16.1, 16.2, 18.1, 19.1, 20.2, 21.2, 23.2, 25.1, 26.1, 27.1, 28.1, 30.1, 36.1, 37.1, 38.1, 39.1, 41.1, 43.1, 45.1, 46.1, 47.1, 48.1, 49.1, 50.1, 51.1, 52.1, 59.1, 60.1, 61.1, 64.1, 65.1, 68.1, 70.1, E1, E2, and E3.

106 . The compound of claim 92 selected from the group consisting of: E1, E2, and E3.

107 . A pharmaceutical composition:

(1) comprising a therapeutically effective amount of at least one compound of claim 92 , or a pharmaceutically acceptable salt, solvate, or ester thereof, and at least one pharmaceutically acceptable carrier, or

(2) comprising a therapeutically effective amount of at least one compound of claim 92 , or a pharmaceutically acceptable salt, solvate, or ester thereof, and at least one pharmaceutically acceptable carrier, and an effective amount of one or more BACE inhibitors,

(3) comprising a therapeutically effective amount of at least one compound of claim 92 , or a pharmaceutically acceptable salt, solvate, or ester thereof, and at least one pharmaceutically acceptable carrier, and effective amount of one or more cholinesterase inhibitors, or

(4) comprising a therapeutically effective amount of at least one compound of claim 92 , or a pharmaceutically acceptable salt, solvate, or ester thereof, and at least one pharmaceutically acceptable carrier, and effective amount of one or more BACE inhibitors, muscarinic antagonists, cholinesterase inhibitors; gamma secretase inhibitors; gamma secretase modulators; HMG-CoA reductase inhibitors; non-steroidal anti-inflammatory agents; N-methyl-D-aspartate receptor antagonists; anti-amyloid antibodies; vitamin E; nicotinic acetylcholine receptor agonists; CB1 receptor inverse agonists or CB1 receptor antagonists; an antibiotic; growth hormone secretagogues; histamine H3 antagonists; AMPA agonists; PDE4 inhibitors; GABA A inverse agonists; inhibitors of amyloid aggregation; glycogen synthase kinase beta inhibitors; promoters of alpha secretase activity; PDE-10 inhibitors and cholesterol absorption inhibitors, or

(5) comprising a therapeutically effective amount of at least one compound of claim 92 , or a pharmaceutically acceptable salt, solvate, or ester thereof, and at least one pharmaceutically acceptable carrier, and an effective amount of donepezil hydrochloride.

108 . A method for treating Alzheimer's Disease, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 92 or a pharmaceutically acceptable salt thereof.

109 . A method for inhibiting the deposition of amyloid protein in, on or around neurological tissue, the method comprising administering to a patient in need thereof an effective amount of a compound according to claim 92 .